Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease

John Vissing1, Morten Duno, Marianne Schwartz

  • 1Department of Neurology 2082, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark. vissing@rh.dk

Insights

A variant form of McArdle disease shows higher exercise capacity due to minimal myophosphorylase activity. This finding establishes the first genotype-phenotype link in McArdle disease, improving muscle oxidative capacity.

Area of Science:

  • Genetics
  • Metabolic myopathies
  • Exercise physiology

Background:

  • McArdle disease results from myophosphorylase gene mutations, typically causing a complete block in muscle glycogenolysis.
  • No genotype-phenotype correlations have been established for McArdle disease due to its uniform presentation.

Purpose of the Study:

  • To investigate the genetic and physiological characteristics of patients with a variant McArdle disease exhibiting high exercise capacity.
  • To establish the first genotype-phenotype correlation in McArdle disease.

Main Methods:

  • Ischemic forearm exercise tests were conducted to measure lactate and ammonia production.
  • Peak oxygen consumption (VO2max) and cardiac output were determined using cycle ergometry.
  • Genetic analysis identified mutations in the myophosphorylase gene.

Main Results:

  • Two patients with atypical McArdle disease showed increased plasma lactate post-exercise and 2-fold higher peak workload and oxidative capacity compared to typical patients.
  • Patients with atypical McArdle disease carried common mutations (R50X, G205S) and novel splice mutations (IVS3-26A>G, IVS5-601G>A).
  • Oxygen uptake relative to cardiac output was impaired in typical McArdle disease but partially normalized in the atypical form.

Conclusions:

  • Minimal myophosphorylase activity, resulting from specific genotypes, ameliorates the McArdle disease phenotype.
  • This milder form of McArdle disease highlights the functional myophosphorylase levels required for muscle oxidative metabolism.
  • The study identifies the first distinct genotype-phenotype relationship in McArdle disease.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mutations01:39

Mutations

Overview
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...